TORONTO, ONTARIO--(Marketwire - December 19, 2007) - PharmEng International Inc. (TSX VENTURE: PII), announced today that its subsidiary, Keata Pharma Inc., has entered into an agreement with Pfizer Canada for Keata to purchase Pfizer’s manufacturing facility in Arnprior, Ontario including inventory. Concurrently, Keata will enter into supply agreements with Pfizer for the exclusive manufacture of certain Pfizer products for Canada at the Arnprior facility for a period of three years. Keata will also manufacture product from the Arnprior location for two other major pharmaceutical clients with multi year supply contracts, becoming a world wide supplier to more than 30 countries.
